The individual and combined influence of HIV and hepatitis C virus on dyslipidaemia in a high-risk Hispanic population

HIV Medicine

Volumn 10, Issue 9, 2009, Pages 555-563

  Forrester, J E ^a   McGovern, B H ^b   Rhee, M S ^c   Sterling, R K ^d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LEMUEL SHATTUCK HOSPITAL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C reactive protein; Dyslipidaemia; HCV; Hispanic; HIV

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RETINOL BINDING PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HEPATITIS C; HIGH RISK POPULATION; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTI-RETROVIRAL AGENTS; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; HEPATITIS C, CHRONIC; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; MALE; RETINOL-BINDING PROTEINS; RISK FACTORS; TRIGLYCERIDES; UNITED STATES;

EID: 70349994614     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00722.x     Document Type: Article

References (62)

1. Imano E, Kanda T, Ishigami Y. Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol 1998, 28:189-193.
2. Ito Y, Takeda N, Ishimori M, Akai A, Miura K, Yasuda K. Effects of long-term interferon-alpha treatment on glucose tolerance in patients with chronic hepatitis C. J Hepatol 1999, 31:215-220.
3. Duong M, Petitie JM, Piroth L. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus co-infected patients undergoing antiretroviral therapy. J Acquir Immune Def Syndr 2001, 27:245-250.
4. Howard AA, Yungtai L, Floris-Moore M, Klein RS, Fleischer N, Schoenbaum EE. Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection. AIDS 2007, 21:633-641.
5. Maggi G, Bottelli R, Gola D. Serum cholesterol and hepatitis C. Ital J Gastroenterol 1996, 28:436-440.
6. Toyoda H, Kumada T. Cholesterol and lipoprotein levels as predictors of response to interferon for hepatitis C. Ann Intern Med 2000, 133:921.
7. Torti C, Patroni A, Tinelli C. Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy. J AIDS 2002, 29:315-317.
8. Patroni A, Torti C, Tomasoni L. Effect of highly active antiretroviral therapy (HAART) and hepatitis C co-infection on hyperlipidemia in HIV-infected patients. HIV Clin Trials 2002, 3:451-461.
9. Polgreen PM, Fultz SL, Justice AC. Association of hypocholesterolemia with hepatitis C virus infection in HIV-infected people. HIV Med 2004, 5:144-150.
10. Flores-Moore M, Howard AA, Lo Y, Schoenbaum EE, Arnsten JH, Klein RS. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDs 2007, 21:479-491.
11. Poynard T, Ratziu V, McHutchison J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38:75-85.
12. Fernandez-Rodrigues CM, Lopez-Serrano P, Alonso S. Long-term reversal of hypocholesterolemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther 2006, 24:507-512.
13. Cooper CL, Mills E, Angel JB. Mitigation of anti-retroviral induced hyperlipidemia by hepatitis C virus coinfection. AIDS 2007, 21:71-76.
14. Carr A, Samaras K, Burton S. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
15. Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol Metab 2001, 12:413-419.
16. Brown TT, Li X, Cole SR. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005, 19:1375-1383.
17. El-Sadr WM, Mullin CM, Carr A. Effects of HIV disease on lipid, glucose and insulin levels. HIV Med 2005, 6:114-121.
18. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989, 86:27-31.
19. Grunfeld C, Pang M, Doerrier W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
20. Constans J, Pellegrin JL, Peuchant E. Plasma lipids in HIV-infected patients. Eur J Clin Invest 1994, 24:416-420.
21. Saint-Marc T, Partisani M, Poizot-Martin I. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy. AIDS 2000, 14:37-49.
22. Hadigan C, Meigs JB, Corcoran C. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32:130-139.
23. Smith C, Levy I, Sabin CA, Kaya E, Johnson MA, Lipman MCI. Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. HIV Med 2004, 5:88-92.
24. http://www.cdc.gov/hiv/resources/Factsheets/PDF/hispanic.pdf, CDC HIV/AIDS Fact Sheet., HIV/AIDS Among Hispanics/Latinos. August 2007. Available at, (accessed 19 June 2008).
25. Therrian M, Ramirez RR. The Hispanic population in the United States. Current Population Reports 2001, 20-535. In, Washington, DC, US Department of Commerce, Bureau of the Census
26. Stern MP, Gaskill SP, Hazuda HP, Gardner LI, Haffner SM. Does obesity explain excess prevalence of diabetes among Mexican Americans? Results of the San Antonio Heart Study. Diabetologia 1983, 24:272-277.
27. Palaniappan LP, Carnethon MR, Fortmann SP. Heterogeneity in the relationship between ethnicity, BMI and fasting insulin. Diabetes Care 2002, 25:1351-1357.
28. Tull ES, Thurland A. Dyslipidemia and insulin resistance in relation to genetic admixture among Hispanics and non-Hispanic blacks of Caribbean origin. J Natl Med Assoc 2004, 96:332-340.
29. Bermudez OI, Tucker KL. Total and central obesity among elderly Hispanics and the association with type 2 diabetes. Obes Res 2001, 9:443-451.
30. Lin H, Bermudez OI, Tucker KL. Dietary patterns of Hispanic elders are associated with acculturation and obesity. J Nutr 2003, 133:3651-3657.
31. Ho RC, Davy KP, Hickey MS, Summers SA, Melby CL. Behavioral, metabolic, and molecular correlates of lower insulin sensitivity in Mexican-Americans. Am J Physiol Endocrinol Metab 2002, 283:E799-E808.
32. Yang Q, Graham TE, Mody N. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
33. Cho YM, Youn BS, Lee H. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006, 29:2457-2461.
34. Choudhry S, Coyle NE, Tang H. Population stratification confounds genetic association of studies among Latinos. Hum Genet 2006, 118:652-664.
35. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis. Clin Chem Acta 1997, 261:159-165.
36. Forrester JE, Sheehan HMB, Joffe TH. A validation study of body composition by bioelectrical impedance analysis in HIV-positive and HIV-negative Hispanic men and women. J Am Diet Assoc 2008, 108:534-538.
37. Tucker KL, Bianchi LA, Maras J, Bermudez OI. Adaptation of a food frequency questionnaire to assess the diets of Puerto Ricans and non-Hispanic adults. Am J Epidemiol 1998, 48:507-518.
38. Sahni S, Forrester JE, Tucker KL. Assessing dietary intake of drug abusing Hispanic adults with and without human immunodeficiency virus infection. J Am Diet Assoc 2007, 107:968-976.
39. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment. Diabetologia 1985, 28:412-419.
40. World Health Organization., Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. WHO/NUT/NCD/98.1. World Health Organization, Geneva, 1997
41. Ginsberg HN, Zhang Y-L, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005, 36:232-240.
42. Jones CY, Wilson IB, Greenberg AS. Insulin resistance in HIV-infected men and women in the nutrition for healthy living cohort. J Acquir Immune Defic Syndr 2005, 40:202-211.
43. Wohl DW, Scherzer R, Heymsfield S. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008, 48:44-52.
44. Magny Bergersen B, Schumacher A, Sandvik L, Bruun JN, Birkeland K. Important differences in components of the metabolic syndrome between HIV-infected patients with and without highly active antiretroviral therapy and healthy controls. Scand J Infect Dis 2007, 38:682-689.
45. Joy T, Keogh HM, Hadigan C. Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS 2007, 21:1591-1600.
46. Lapadula G, Torti C, Paraninfo G. Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther 2006, 11:521-527.
47. De Socio GV, Bonfani P, Ricci E. Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r. Biomed Pharmacother 2008, 62:16-20.
48. Siagris D, Christofidou M, Theocharis GJ. Serum lipid pattern in chronic hepatitis C. J Viral Hepatitis 2006, 13:56-61.
49. Reingold JS, Wanke C, Kotler DP. Association of HIV infection and HIV/HCV co-infection with C-reactive protein levels. J Acquir Immune Defic Syndr 2008, 48:142-148.
50. Aeberli I, Biebinger R, Lehmann R, L'Allemand D, Spinas GA, Zimmermann MB. Serum retinol binding protein-4 concentration and its ratio to serum retinol are associated with obesity and metabolic syndrome components in children. J Clin Endocrinol Metab 2007, 92:4359-4365.
51. Qi Q, Yu Z, Ye X. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab 2007, 92:4827-4834.
52. Lim S, Choi SH, Jeong IK. Insulin sensitizing effects of exercise on adiponectin and retinol-binding protein-4 concentrations in young and middle-aged women. J Clin Endocrinol Metab 2008, 93:2263-2268.
53. Reinehr T, Stoffel-Waghner B, Roth CL. Retinol-binding protein 4 and it relation to insulin resistance in obese children before and after weight loss. J Clin Endocrinol Metab 2008, 93:2287-2293.
54. Promintzer M, Krebs M, Todoric J. Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab 2007, 92:4306-4312.
55. Janke J, Engeli S, Boschmann M. Retinol-binding protein in human obesity. Diabetes 2006, 55:2805-2810.
56. Yagmur E, Weiskirchen R, Gressner AM, Trautwein C, Tacke F. Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4. Diabetes Care 2007, 30:1168-1172.
57. Thomseen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol 1992, 181:293-300.
58. Prince AM, Huima-Byron T, Parker TS, Levine DM. Visualization of hepatitis C virons and putative defective interfering particles isolated from low-density lipoproteins. J Viral Hepat 1996, 3:11-17.
59. Monazahian M, Bohme I, Bonk S. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999, 57:223-229.
60. Molina S, Castet V, Fournier-Wirth C. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007, 46:411-419.
61. Favre D, Muellhaupt B. Potential cellular receptors involved in hepatitis C virus entry into cells. Lipids Health Disease 2005, 4:9.
62. Nainan OV, Alter MJ, Kruszon-Moran D. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterol 2006, 131:478-484.